Moehler, Markus; Janjigian, Yelena Y.; Shitara, Kohei et al.
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMateONCOLOGY RESEARCH AND TREATMENT. Bd. 47. 2024 S. 64-64
Shitara, Kohei; Moehler, Markus H.; Ajani, Jaffer A. et al.
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 3_SUPPL. 2024 S. 306-306
Elimova, Elena; Shitara, Kohei; Moehler, Markus H. et al.
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 16. 2024
Galle, Peter Robert; Decaens, Thomas; Kudo, Masatoshi et al.
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 17_SUPPL. 2024 S. LBA4008-LBA4008
Hahad, Omar; Gilan, Donya; Michal, Matthias et al.
Noise annoyance and cardiovascular disease risk: results from a 10-year follow-up studySCIENTIFIC REPORTS. Bd. 14. H. 1. 2024
Michel, Maurice; Doll, Michelle; Albert, Nastasia et al.
Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetesUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 12. H. 1. 2024 S. 11-21
Gottwald-Hostalek, Ulrike; Kahaly, George J.
Optimizing levothyroxine treatment for subclinical hypothyroidism during pregnancyCURRENT MEDICAL RESEARCH AND OPINION. Bd. 40. H. 1. 2024 S. 43-49
Scheiner, Bernhard; Kang, Beodeul; Balcar, Lorenz et al.
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyHEPATOLOGY. Bd. 81. H. 6. 2024 S. 1714-1727
Bauer, Ulrike; Ben Khaled, Najib; Grottenthaler, Julia M. et al.
Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitor-based therapy-first results from an international multicenter registryJOURNAL OF HEPATOLOGY. Bd. 80. 2024 S. S440-S441
Keggenhoff, Friederike L.; Castven, Darko; Becker, Diana et al.
PARP-1 selectively impairs <i>KRAS</i>-driven phenotypic and molecular features in intrahepatic cholangiocarcinomaGUT. Bd. 73. H. 10. 2024 S. 1712-1724